FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical composition for local introduction on the surface of epithelial tissue barrier, which contains scFv-antibodies, which specifically bind selected antigens and can be obtained by the method, including (i) selection from pool of soluble and stable frames of antibodies of soluble and stable frame, corresponding in the best way to the frame of non-human antibody against antigen with definite binding specificity, (ii) either providing said soluble and stable frame of CDR which bind specifically with said antigen, either mutation of this frame of said non-human antibody in direction of sequence of said soluble and stable frame for generation of scFv-antibodies, (iii) testing generated antibody for solubility and stability, and testing generated antibody for antigen binding and (iv) selection of scFv-antibody, which is stable, soluble and specifically binds with this antigen.
EFFECT: invention ensures improved ability of composition penetration into tissue.
37 cl, 10 ex, 3 tbl, 19 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION ON SURFACE OF EPITHELIUM BARRIER, CONTAINING ANTIBODIES PERMEATING THROUGH THIS BARRIER | 2011 |
|
RU2565399C2 |
| STABLE AND SOLUBLE VEGF INHIBITING ANTIBODIES | 2018 |
|
RU2696972C1 |
| VEGF INHIBITING STABLE AND SOLUBLE ANTIBODIES | 2009 |
|
RU2531523C9 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2009 |
|
RU2588467C2 |
| HUMANIZATION OF RABBIT ANTIBODIES USING THE UNIVERSAL ANTIBODY FRAME | 2014 |
|
RU2652907C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2016 |
|
RU2648152C2 |
| HUMANISATION OF RABBIT ANTIBODIES USING UNIVERSAL ANTIBODY SCAFFOLD | 2009 |
|
RU2567006C2 |
| HUMANIZING RABBIT ANTIBODIES USING A UNIVERSAL ANTIBODY FRAMEWORK | 2018 |
|
RU2696202C1 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
